Evidence map›Paper›PMID 33768100›Full record

ArticleFrontiers in medicine2021

D-Limonene Is a Potential Monoterpene to Inhibit PI3K/Akt/IKK-α/NF-κB p65 Signaling Pathway in Coronavirus Disease 2019 Pulmonary Fibrosis.

Fan Yang, Ru Chen, Wan-Yang Li, Hao-Yue Zhu, Xiao-Xuan Chen, Zhen-Feng Hou, Ren-Shuang Cao, GuoDong Zang, Yu-Xuan Li, Wei Zhang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Integrated bioinformatics andFrontiers in nutrition · 2022
    Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Fan YangCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Ru ChenBiomedical Research Institute of Fudan University, Shanghai, China.
Wan-Yang LiSchool of Public Health, Xiangya Medical College, Central South University, Changsha, China.
Hao-Yue ZhuCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Xiao-Xuan ChenCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Zhen-Feng HouCollege of Life Sciences, Shandong Normal University, Jinan, China.
Ren-Shuang CaoCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
GuoDong ZangDepartment of Pulmonary Diseases, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
Yu-Xuan LiSecond School of Clinical Medicine, Beijing University of Chinese Medicine, Beijing, China.
Wei ZhangDepartment of Pulmonary Diseases, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
Shandong University of Traditional Chinese Medicine · CNAffiliated Hospital of Shandong University of Traditional Chinese Medicine · CNBeijing University of Chinese Medicine · CNCentral South University · CNFudan University · CNShandong Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

At the time of the prevalence of coronavirus disease 2019 (COVID-19), pulmonary fibrosis (PF) related to COVID-19 has become the main sequela. However, the mechanism of PF related to COVID (COVID-PF) is unknown. This study aimed to explore the key targets in the development of COVID-PF and the mechanism of d-limonene in the COVID-PF treatment. The differentially expressed genes of COVID-PF were downloaded from the GeneCards database, and their pathways were analyzed. d-Limonene was molecularly docked with related proteins to screen its pharmacological targets, and a rat lung fibrosis model was established to verify d-limonene's effect on COVID-PF-related targets. The results showed that the imbalance between collagen breakdown and metabolism, inflammatory response, and angiogenesis are the core processes of COVID-PF; and PI3K/AKT signaling pathways are the key targets of the treatment of COVID-PF. The ability of d-limonene to protect against PF induced by bleomycin in rats was reported. The mechanism is related to the binding of PI3K and NF-κB p65, and the inhibition of PI3K/Akt/IKK-α/NF-κB p65 signaling pathway expression and phosphorylation. These results confirmed the relationship between the PI3K-Akt signaling pathway and COVID-PF, showing that d-limonene has a potential therapeutic value for COVID-PF.

Indexed as

coronavirus disease 2019coronavirus disease related pulmonary fibrosisD-limonenePI3K/Akt signaling pathwaysevere acute respiratory syndrome

Identifiers

PMID33768100
PMCPMC7985179
OpenAlexW3133990125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.